*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *       

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Cost of illness of hypertension from the perspective of patients using a patient-based survey in several primary healthcare centers and a hospital in Yogyakarta, Indonesia

Author: DWI ENDARTI, ANNA WAHYUNI WIDAYANTI, GITA WANDANSARI, SHERLY NOVENTI
Abstract: Objective: Hypertension is a serious medical condition that causes high health and economic burden. This study aimed to estimate cost of illness of hypertension from patient’s perspective. Methods: This was a cross sectional study applying a prevalence-based cost of illness study. Data including direct medical costs, direct nonmedical costs and indirect costs were collected by interviewing patients using recall method. The study recruited patients under the national health insurance scheme as study respondents, which consisted of 99 patients visiting 3 public primary healthcare centers and 30 patients visiting private secondary hospital in Yogyakarta Province, Indonesia. Results: Based on patients’ perspective in Yogyakarta-Indonesia, the average cost of illness of hypertension within 3 months period was IDR 53,771 (USD 3.71) and IDR 375,126 (USD 25.87) for patients at PHCs and hospital, respectively. The costs were about 1 - 7% of the minimum wage rate of Yogyakarta Province. Indirect cost contributed to the highest component of cost of illness which accounted for 76 – 80%. Conclusion: This study informed that hypertension had impact on out-of-pocket cost of treatment and further productivity loss of patients and their caregivers. This study also provided cost information as parameter input for further pharmacoeconomic study.
Keyword: hypertension, chronic disease, catastrophic illness, cost analysis, pharmacoeconomic
DOI: https://doi.org/10.31838/ijpr/2021.13.01.477
Download: Request For Article
 
Clients

Clients

Clients

Clients

Clients
ONLINE SUBMISSION
USER LOGIN
Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free